Clinical Trial Update: Regadenoson Real Time Perfusion Imaging Trial-Optison [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating regadenoson real-time perfusion imaging with Optison has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Ischemic Heart Disease

Drugs mentioned

• Lexiscan (regadenoson) (regadenoson)
• Optison

Snippet

Sponsor: University of Nebraska | Conditions: Coronary Artery Disease, Myocardial Perfusion Abnormalities | Phase 3 | Status: COMPLETED | Results posted: 2022-12-30